Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

679020.pdf (158.39 KB)

Document type

Article

Version

Published version

Publication date

2018-03-12

Publication license

cc-by (c) Franco Fernández, Rafael et al., 2018
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/139398

Adenosine A2A receptor antagonists in neurodegenerative diseases:Huge potential and huge challenges

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3389/fpsyt.2018.00068

Abstract

In this opinion paper, we provide scientific-based reasons about the huge therapeutic potential of adenosine A2A receptor antagonists, and about the huge challenges to demonstrate efficacy in clinical trials, i.e., to provide data now required to approve a new medication by the regulatory bodies, such as U.S. Food and Drug Administration (FDA). Adenosine is an autacoid present in all tissue and body fluids. Adenosine, whose extracellular concentration is controlled by producing/degrading enzymes and by nucleoside transporters, acts via four (A1, A2A, A2B, and A3) specific cell surface receptors that belong to the superfamily of G-protein-coupled receptors. For decades, adenosine receptors have shown promise as targets of medications for a variety of ailments. Until recently, however, the only approved medicine was adenosine itself, i.e., the endogenous agonist, to combat arrhythmias, such as paroxysmal supraventricular tachycardia (1-3). Prospects are changing as the first medication targeting selectively the adenosine A2A receptor has been approved few years ago in Japan. The recently approved drug is an antagonist, i.e., a receptor blocker (see later). A2A receptor antagonists show promise in neuroprotection, although for Huntington's or Niemann Pick's diseases it is suggested that antagonists may be detrimental and/or there is controversy on which is the efficacious intervention, i.e., receptor activation or blockade [see Ref. (4-9) and references therein].

Subject

Malalties neurodegeneratives, Adenosina

Subject (English)

Neurodegenerative Diseases, Adenosine

Citation

Collections

Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Articles publicats en revistes (Bioquímica i Fisiologia)

Citation

FRANCO FERNÁNDEZ, Rafael and NAVARRO BRUGAL, Gemma. Adenosine A2A receptor antagonists in neurodegenerative diseases:Huge potential and huge challenges. Frontiers In Psychiatry. 2018. Vol. 9, num. 68. ISSN 1664-0640. [consulted: 12 of August of 2026]. Available at: https://hdl.handle.net/2445/139398

Export metadata

JSON - METS

Share record